Contemporary Management of Knee Chondral Defects, Part II: Structural Cartilage Restoration with Focal Resurfacing Implants and Osteochondral Autograft Transfer
The Journal of Knee Surgery · 01.11.2026 · 39 (13) · 678-687
DOI: 10.1055/a-2865-1789 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Knee Surgery, erschienen am 01.11.2026. Verfasst von Chase W Smitterberg und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, LifeBridge Health Rubin Institute for Advanced Orthopedics, Baltimore, Maryland, United States. Hauptthemen laut MEDLINE: Cartilage, Articular, Knee Joint, Bone Transplantation, Cartilage Diseases. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Structural cartilage restoration strategies provide mechanical solutions for focal knee chondral defects in which biologic repair alone is unlikely to withstand load-bearing demands. These approaches are most applicable to discrete lesions in otherwise preserved joints where restoration of articular congruity and immediate mechanical stability are required. This review evaluates focal resurfacing implants and osteochondral autograft transfer system procedures as structural joint-preserving interventions. Contemporary metal and polymer-based focal implants demonstrate meaningful short- to mid-term improvements in pain and function. However, registry data and meta-analyses reveal variable survivorship and revision risk, frequently related to progressive osteoarthritis or implant-related complications. Outcomes are highly dependent on appropriate patient selection and precise implant positioning. Osteochondral autograft transfer system procedures and mosaicplasty restore mature hyaline cartilage and subchondral bone using autologous osteochondral plugs. Long-term series extending beyond a decade support durable outcomes in small, contained lesions. Donor-site morbidity, graft contouring limitations, and size constraints, however, restrict broader applicability. Comparative data highlight trade-offs between mechanical resurfacing and cartilage transfer. Implants avoid donor harvest, but introduce device survivorship concerns and complex revision pathways. Autograft transfer offers established durability with native tissue, but carries technical constraints and harvest-related morbidity. Structural restoration strategies occupy a defined position within the cartilage preservation continuum. Their success depends on alignment between defect characteristics, patient activity demands, and the surrounding joint environment. When applied within appropriate indications, these techniques can provide durable symptom relief, though none of them eliminates the risk of progression to arthroplasty.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, LifeBridge Health Rubin Institute for Advanced Orthopedics, Baltimore, Maryland, United States.
- Department of Orthopedic Surgery, Northwell Health, Lenox Hill Hospital, New York, New York, United States.
ORCID-Profile: Chase W Smitterberg
Zitieren
APA
Smitterberg, C. W., Scuderi, G. R., & Mont, M. A. (2026). Contemporary Management of Knee Chondral Defects, Part II: Structural Cartilage Restoration with Focal Resurfacing Implants and Osteochondral Autograft Transfer. The Journal of Knee Surgery, 39(13), 678-687. https://doi.org/10.1055/a-2865-1789
Vancouver
Smitterberg CW, Scuderi GR, Mont MA. Contemporary Management of Knee Chondral Defects, Part II: Structural Cartilage Restoration with Focal Resurfacing Implants and Osteochondral Autograft Transfer. The Journal of Knee Surgery. 2026;39(13):678-687. doi:10.1055/a-2865-1789
BibTeX
@article{Smitterberg2026,
author = {Smitterberg, Chase W and Scuderi, Giles R and Mont, Michael A},
title = {Contemporary Management of Knee Chondral Defects, Part II: Structural Cartilage Restoration with Focal Resurfacing Implants and Osteochondral Autograft Transfer},
journal = {The Journal of Knee Surgery},
year = {2026},
volume = {39},
number = {13},
pages = {678--687},
doi = {10.1055/a-2865-1789}
}
EUVIMED